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For genomic medicine research to be fully translated
into clinical care, it is critical for researchers to engage
stakeholders who ultimately regulate the use of
genomic technologies and therapeutics within
healthcare practice. Herein, we describe an example of
how this might work.Clinical Sequencing Exploratory Research (CSER; https://
cser-consortium.org/), Implementing Genomics in PracticeNeed for stakeholder engagement
Notwithstanding the historical hype of genomic medicine
[1], there is growing evidence demonstrating successful
clinical applications for genomic technologies, particularly
for inherited disease diagnosis [2]. Genomic testing is also
increasingly used in clinical cancer management and
pharmacogenomics [3, 4].
Producing the evidence is but the first step toward imple-
mentation of genomic medicine. Efforts to engage with tar-
get communities and patient stakeholders are now a
frequent component of clinical genomics research proto-
cols [5]. Successful partnerships have been demonstrated to
increase satisfaction, trust, and ultimate uptake of results.
However, for the benefits of genomic medicine research to
be realized “at the bedside” by the public who funds it, it is
critical to address the role of entities that regulate different
aspects of healthcare. These roles include both the regula-
tion of the tests and technologies as well as reimbursement
or coverage decisions for the utilization of these technolo-
gies in clinical practice. These regulatory roles are crucially
important to ensure that novel research findings are safe
and effective for standard clinical practice. Although there
is recognition of the need to engage regulatory stakeholders
for clinical genomic research [6], more progress is needed.
Perhaps there are lessons to be learned from the struc-
ture of successful patient–researcher partnerships
which emphasize co-learning and capacity building, it-
erative processes, dissemination of results among all* Correspondence: Julianne_ODaniel@med.unc.edu
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lationships [7].
Currently, many of the research programs producing the
growing body of evidence for healthcare applications of gen-
omic medicine are associated with or directly linked through
large-scale consortia funded by the National Human Gen-
ome Research Institute (NHGRI), under the purview of the
National Institutes of Health (NIH). Examples include
(IGNITE; https://ignite-genomics.org/), and Clinical Gen-
ome Resource (ClinGen; https://www.clinicalgenome.org/).
A primary aim of these public-funded projects is to elucidate
whether and how genomic technologies can be utilized to
improve patient outcomes and optimize healthcare for the
population and individual. In other words, much of research
is focused on the analytic and clinical validity as well as clin-
ical utility of genomic technologies. Researchers’ definitions
of these concepts may vary considerably from that of regula-
tory groups, however. Rather than producing scientific
evidence with the assumption that it will meet the evidence
requirements for policy development, it is important to en-
gage individuals making both coverage and regulatory deci-
sions to understand the evidence needs and assessment
processes of these stakeholders. Such engagement may fa-
cilitate understanding between researchers and regulators
and help ensure study designs and outcomes achieve their
intended goals.Developing a framework for engagement
The ClinGen program has begun to develop such en-
gagement partnerships. The central aim of ClinGen is to
build an authoritative resource that defines the clinical
relevance of genes and variants for use in clinical re-
search and medicine [8]. Regulatory groups tasked with
assessing the clinical validity of genomic medicine appli-
cations have a vested interest in the outcomes of
ClinGen. To begin developing the relationship between
researchers and external stakeholders, it is important to
define who the regulatory stakeholders may include. For
ClinGen, these include groups tasked with ensuring thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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those that regulate (1) the development of tests, (2) the
assignment of procedural codes used to define intended
use of a genomic test, and (3) the decisions regarding
the appropriate clinical use of genomic testing via health
policy for medical coverage and reimbursement. Add-
itional stakeholders include professional societies who
may produce guidelines utilized by regulatory bodies
and patients who share access to clinical genome data.
In order to build mutually beneficial relationships, it is
then important to explore the various groups’ role(s) in
genomic medicine and their evidence/data needs for pol-
icy development and decision-making. Key questions
may include the following: (1) What is each regulatory
group’s role(s) in genomic medicine and how can re-
search efforts contribute to their specific aims? (2) What
types of evidence are needed to support each group’s
regulatory decisions? (3) Do the research aims align with
the evidentiary needs and/or can the study protocol be
amended in response to the required data/evidence? (4)
Are there mutual benefits to establishing a relationship?
(5) Is it feasible to build and sustain a relationship of
transparency, communication, and dissemination?
The US Food and Drug Administration (FDA) pro-
actively expressed interest in ClinGen’s approach to cur-
ation of genes and variants. Based on this interest,
ClinGen sought to establish a process of engagement
with the FDA as the first stakeholder. The interactions(a)
(b)
Fig. 1 a Overview of the regulatory stakeholder relationship established be
Food and Drug Administration (FDA). The two groups defined their commo
and share progress. b Summary of the dynamics and benefits of partneringto date between ClinGen researchers and the FDA de-
scribed here are presented as an example of how such
engagement could work. To facilitate the development
of this stakeholder relationship, a small workgroup of
key program contacts/liaisons from the relevant organi-
zations (ClinGen, NHGRI, and FDA) met monthly via
conference calls. At the outset, roles and interests were
defined as summarized in Fig. 1a.
The open dialogue generated by establishing this relation-
ship has provided a means through which to clarify and/or
contextualize confusing or misunderstood jargon and con-
cepts in terms of the research and the regulatory processes.
Acknowledging the need for shared learning is essential to
building a mutually respectful relationship. The formal
development of a dedicated liaison and workgroup tasked
with engaging regulatory groups has allowed broader
contextualization of overarching goals and minimized the
possibility for ambiguous messages or distorted perceptions.
The relationship has allowed ClinGen researchers to
understand the potential uses of ClinGen resources
for FDA regulatory purposes and to align curation
processes to produce a resource consistent with FDA
draft guidelines on regulatory-grade databases [9].
The accompanying announcement reflected the FDA’s
perspective on such relationships as helping to
“conceptualize this flexible approach that strikes the
important balance between safeguarding public health
and promoting innovation” [10].tween the Clinical Genome Resource (ClinGen) and the United States
n goals and developed transparent communications to seek insight
with community and regulatory stakeholders
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Through this experience, it has become evident that en-
gaging with regulatory stakeholders, such as the FDA, can
not only be helpful in the development of the ClinGen re-
source, but is essential to guiding appropriate utilization
of the generated evidence to support improved health
through genomic medicine (Fig. 1b). This experience rep-
resents merely the first step in engaging relevant regula-
tory stakeholders and was simplified as the interaction
was focused on a single stakeholder. Ongoing and future
efforts to establish interactions with additional stake-
holders such as those representing payer and reimburse-
ment perspectives, as well as clinical authorities who may
wish to use ClinGen products in making recommenda-
tions, present exciting new challenges, as designing studies
and outcomes that are responsive to a broader range of
decision-makers will require considerable flexibility.
The need for continued and increased regulatory en-
gagement activities among genomic medicine research is
great, and the potential impact of these types of interac-
tions to further clinical genomic medicine may be well
worth the effort.
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